|
1
|
Dechering K, Boersma C and Mosselman S:
Estrogen receptors alpha and beta: two receptors of a kind? Curr
Med Chem. 7:561–576. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song C, Wang J, Song Q, et al: Simvastatin
induces estrogen receptor-alpha (ER-alpha) in murine bone marrow
stromal cells. J Bone Miner Metab. 26:213–217. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park JB: Effects of low dose of estrone on
the proliferation, differentiation and mineralization of
osteoprecursor cells. Exp Ther Med. 4:681–684. 2012.PubMed/NCBI
|
|
4
|
Dauvois S, Danielian PS, White R and
Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen
receptor content by increasing its turnover. Proc Natl Acad Sci
USA. 89:4037–4041. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Curran M and Wiseman L: Fulvestrant.
Drugs. 61:807–814. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Osborne CK, Wakeling A and Nicholson RI:
Fulvestrant: an oestrogen receptor antagonist with a novel
mechanism of action. Br J Cancer. 90(Suppl 1): S2–S6. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fawell SE, White R, Hoare S, Sydenham M,
Page M and Parker MG: Inhibition of estrogen receptor-DNA binding
by the ‘pure’ antiestrogen ICI 164,384 appears to be mediated by
impaired receptor dimerization. Proc Natl Acad Sci USA.
87:6883–6887. 1990.
|
|
8
|
Nicholson RI, Gee JM, Manning DL, Wakeling
AE, Montano MM and Katzenellenbogen BS: Responses to pure
antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and
-resistant experimental and clinical breast cancer. Ann NY Acad
Sci. 761:148–163. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brennan O, O’Brien FJ and McNamara LM:
Estrogen plus estrogen receptor antagonists alter mineral
production by osteoblasts in vitro. Horm Metab Res. 44:47–53. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lykkesfeldt AE, Larsen SS and Briand P:
Human breast cancer cell lines resistant to pure anti-estrogens are
sensitive to tamoxifen treatment. Int J Cancer. 61:529–534. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Cupis A, Noonan D, Pirani P, Ferrera A,
Clerico L and Favoni RE: Comparison between novel steroid-like and
conventional nonsteroidal antioestrogens in inhibiting oestradiol-
and IGF-I-induced proliferation of human breast cancer-derived
cells. Br J Pharmacol. 116:2391–2400. 1995.
|
|
12
|
Robinson JA, Harris SA, Riggs BL and
Spelsberg TC: Estrogen regulation of human osteoblastic cell
proliferation and differentiation. Endocrinology. 138:2919–2927.
1997.PubMed/NCBI
|
|
13
|
Park JB, Zhang H, Lin CY, et al:
Simvastatin maintains osteoblastic viability while promoting
differentiation by partially regulating the expressions of estrogen
receptors α. J Surg Res. 174:278–283. 2012.PubMed/NCBI
|
|
14
|
Park JB: The effects of dexamethasone,
ascorbic acid, and β-glycerophosphate on osteoblastic
differentiation by regulating estrogen receptor and osteopontin
expression. J Surg Res. 173:99–104. 2012.
|
|
15
|
Park JB: Combination of simvastatin and
bone morphogenetic protein-2 enhances differentiation of
osteoblasts by regulating the expression of phospho-Smad1/5/8. Exp
Ther Med. 4:303–306. 2012.PubMed/NCBI
|
|
16
|
Park JB: Effects of fibroblast growth
factor 2 on osteoblastic proliferation and differentiation by
regulating bone morphogenetic protein receptor expression. J
Craniofac Surg. 22:1880–1882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park JB: Effects of doxycycline,
minocycline, and tetracycline on cell proliferation,
differentiation, and protein expression in osteoprecursor cells. J
Craniofac Surg. 22:1839–1842. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Almazin SM, Dziak R, Andreana S and
Ciancio SG: The effect of doxycycline hyclate, chlorhexidine
gluconate, and minocycline hydrochloride on osteoblastic
proliferation and differentiation in vitro. J Periodontol.
80:999–1005. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fotakis G and Timbrell JA: In vitro
cytotoxicity assays: comparison of LDH, neutral red, MTT and
protein assay in hepatoma cell lines following exposure to cadmium
chloride. Toxicol Lett. 160:171–177. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qu Q, Perälä-Heape M, Kapanen A, et al:
Estrogen enhances differentiation of osteoblasts in mouse bone
marrow culture. Bone. 22:201–209. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi H, Aguiar DJ, Williams SM, La Pean A,
Pan W and Verfaillie CM: Identification of genes responsible for
osteoblast differentiation from human mesodermal progenitor cells.
Proc Natl Acad Sci USA. 100:3305–3310. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Quarles LD, Yohay DA, Lever LW, Caton R
and Wenstrup RJ: Distinct proliferative and differentiated stages
of murine MC3T3-E1 cells in culture: an in vitro model of
osteoblast development. J Bone Miner Res. 7:683–692. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gallagher A, Chambers TJ and Tobias JH:
The estrogen antagonist ICI 182,780 reduces cancellous bone volume
in female rats. Endocrinology. 133:2787–2791. 1993.PubMed/NCBI
|
|
24
|
Sato K, Nohtomi K, Shizume K, et al: 17
beta-estradiol increases calcium content in fetal mouse parietal
bones cultured in serum-free medium only at physiological
concentrations. Bone. 19:213–221. 1996. View Article : Google Scholar
|
|
25
|
Wakeling AE: The future of new pure
antiestrogens in clinical breast cancer. Breast Cancer Res Treat.
25:1–9. 1993. View Article : Google Scholar : PubMed/NCBI
|
